Share

    


In This Section

Home / News & Media / Oncology Newsfeed

Oncology Newsfeed

  • FDA Approves Tebentafusp-tebn for Unresectable or Metastatic Uveal Melanoma

    On Wednesday, January 26, 2022, the U.S. Food and Drug Administration (FDA) approved tebentafusp-tebn for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. 

    Read Immunocore's announcement.

    Posted 1/26/2022



  • FDA Approves Illuccix for Prostate Cancer Imaging

    On December 20, 2021, the U.S. Food and Drug Administration (FDA) approved Illuccix®, a kit for the preparation of gallium-68 (68Ga) gozetotide (also known as PSMA-11) injection, which is a radioactive diagnostic agent indicated for positron emission tomography of prostate-specific membrane antigen positive lesions in patients with prostate cancer with:

    • suspected metastasis who are candidates for initial definitive therapy
    • suspected recurrence based on elevated serum prostate-specific antigen level.
    For more information, read Telix Pharmaceuticals' announcement.


  • GSK Launches Target the Future for the Multiple Myeloma Community

    GlaxoSmithKline (GSK) launched its new campaign Target the Future to address the current challenges patients with multiple myeloma and healthcare providers face. This campaign will provide education, identify key challenges the multiple myeloma community faces, and facilitate solutions to create a better future for patients, caregivers, and loved ones.

    A component of this campaign is the Target the Future Think Tank Challenge, which is now accepting idea submissions. The winner will receive a $100,000 grant to bring their idea to life.

    For more information on this campaign and how you can get involved, read GSK's announcement.

    Posted 12/16/2021


  • FDA Approves NGS-Based CDx for Non-Small Cell Lung Cancer

    On December 9, 2021, the U.S. Food and Drug Administration (FDA) granted premarket approval to Oncomine Dx Target Test as a companion diagnostic (CDx) to help identify patients with non-small cell lung cancer whose tumors carry epidermal growth factor receptor Exon20-insertion mutations for potential treatment with Rybrevant® (amivantamab-vmjw).

    Read ThermoFisher Scientific's announcement.

    Posted 12/10/2021



  • New CMS Data Shows Increased Medicare Telemedine Utilization During COVID-19

    On December 3, 2021, the Centers for Medicare and Medicaid Services (CMS) released a new data snapshot, featuring telemedicine utilization data that make the case for expanded and permanent telehealth coverage for Medicare beneficiaries.

    These data are about people with Medicare who used telemedicine services between March 1, 2020, and February 8, 2021, and they come from Medicare Fee-for-Service data, Medicare Advantage encounter data, and Medicare enrollment information.

    CMS states that the agency has seen large increases in telemedicine use during the defined time frame with variations across geographic and demographic groups. This increase is credited to the agency's expansion of telemedicine services during the COVID-19 public health emergency.

    The snapshot shows that telemedicine utilization (e.g., telehealth, e-visits, and virtual check-ins) increased from 910,490 unique users pre-pandemic to 28,255,180 unique users during the pandemic. And the majority (53%) of the pandemic's telemedicine users were Medicare beneficiaries. To see a detailed breakdown of these data, read the full snapshot report.

    For more information on Medicare's telemedicine expansions, visit its dedicated telehealth website.

    Posted 12/9/2021


  • FDA Approves FoundationOne®CDx as a Companion Diagnostic in Melanoma

    On December 8, 2021, the U.S. Food and Drug Administration (FDA) approved FoundationOne®CDx to be used as a companion diagnostic for two groups of current and future FDA-approved therapeutics in melanoma, which includes BRAF inhibitor monotherapies targeting BRAFV600E and BRAF/MEK inhibitor combination therapies targeting BRAFV600E or V600K mutations. 

    Read the Foundation Medicine announcement.

    Posted 12/8/2021



  • LeanTaaS Announces Transform Virtual Summit

    LeanTaaS will be hosting its Transform Hospital Operations Virtual Summit, which will feature a keynote address from Dr. Scott Gottlieb, from December 7 to 8. This event is hosted in partnership with Becker's Healthcare. 

    Health system executives, technology leaders, and industry experts will be brought together to discuss solutions for current pressing issues for health systems, such as backlog challenges, staffing shortages and burnout, as increased patient wait times. 

    Registration is free for all attendees. Go online to view the event's agenda and to register.

    Posted 12/6/2021


  • FDA Approves Rituximab + Chemotherapy for Pediatric Cancer Indications

    On December 2, 2021, the U.S. Food and Drug Administration approved rituximab in combination with chemotherapy for pediatric patients (greater than or equal to 6 months to less than 18 years) with previously untreated, advanced stage, CD20-positive diffuse large B-cell lymphoma, Burkitt lymphoma, Burkitt-like lymphoma, or mature B-cell acute leukemia. 

    Read the FDA announcement.

    Posted 12/6/2021



  • FDA Approves Pembrolizumab for IIB or IIC Melanoma Following Complete Resection

    On December 3, 2021, the U.S. Food and Drug Administration approved Keytruda® (pembrolizumab) for the adjuvant treatment of adult and pediatric (greater than or equal to 12 years of age) patients with stage IIB or IIC melanoma following complete resection. 

    Read the FDA announcement.

    Read Merck's announcement.

    Posted 12/6/2021



  • FDA Approves Daratumumab and Hyaluronidase-fihj in Combination for MM

    On November 30, 2021, the U.S. Food and Drug Administration (FDA) approved daratumumab and hyaluronidase-fihj in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (MM) who have received one to three prior lines of therapy.

    Read the FDA announcement.

    Read Janssen, Inc.'s announcement.

    Posted 12/2/2021